Johnson & Johnson (JNJ) Offering Possible 6.61% Return Over the Next 7 Calendar Days

Johnson & Johnson’s most recent trend suggests a bearish bias. One trading opportunity on Johnson & Johnson is a Bear Call Spread using a strike $167.50 short call and a strike $172.50 long call offers a potential 6.61% return on risk over the next 7 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $167.50 by expiration. The full premium credit of $0.31 would be kept by the premium seller. The risk of $4.69 would be incurred if the stock rose above the $172.50 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Johnson & Johnson is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Johnson & Johnson is bearish.

The RSI indicator is at 32.85 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Johnson & Johnson

EU foregoes 100 million J&J vaccines, considers donating other doses – sources
Thu, 10 Jun 2021 09:25:33 +0000
The European Union decided not to take up an option to buy 100 million doses of the Johnson & Johnson’s COVID-19 vaccine and is considering donating another 100 million optional shots, if ordered, European officials said. The discussions show a drop in confidence in the one-dose shot, which was initially touted as crucial for a successful vaccination drive in Europe, but has been largely relegated to a back-up choice after safety and supply problems.

“The beginning of the end is here for covid, vaccination is key”: Doctor
Wed, 09 Jun 2021 21:20:24 +0000
Dr. Sejal Hathi, Physician & Clinical Fellow at Massachusetts General Hospital and host of “Civic Rx” podcast, joined Yahoo Finance to discuss the latest on covid-19.

Czech health ministry recommends AstraZeneca, J&J jabs only for over-60s
Wed, 09 Jun 2021 18:53:01 +0000
The Czech health ministry recommended on Wednesday that only people over 60 years old should receive COVID-19 vaccines from AstraZeneca and Johnson & Johnson due to a potential risk of blood clots. Scientists and U.S. and European drug regulators have been searching for an explanation for what is causing rare but potentially deadly clots accompanied by low blood platelet counts, which have led some countries to halt or limit use of the AstraZeneca and J&J vaccines. The Czech health ministry said it made the decision after responding to recommendations from the country’s drug regulator SUKL and the Czech Vaccination Society.

Roivant’s Datavant, Ciox Health To Merge In $7B Deal
Wed, 09 Jun 2021 17:43:27 +0000
As Roivant Sciences looks to reacquire one of its spinouts, another one is merging with a rival at a massive valuation. Datavant, Roivant’s real-world evidence, and health data play will merge with the electronic-health record management firm Ciox Health in a transaction that will value the combined company at $7 billion. The merged company claims that it has $700 million in annual revenue. To be named Datavant, the combined company will allow a secure exchange of data among its network, which i

UPDATE 2-Nigeria to borrow $1.76 bln for security spending –FinMin
Wed, 09 Jun 2021 16:53:35 +0000
Nigeria plans to borrow 722.53 billion naira ($1.76 billion) from domestic capital markets for additional security spending, Finance Minister Zainab Ahmed said on Wednesday. As part of Nigeria’s security spending, the World Bank also agreed to allow the government to restructure existing loans of 39.58 billion naira to supplement the funds, she told reporters after a cabinet meeting. The cabinet also approved an allocation of 83.56 billion naira for the purchase and deployment of 30 million doses of the Johnson & Johnson COVID-19 vaccine.

Be Sociable, Share!

Related Posts